Emergent BioSolutions has announced its plans to stock a new Narcan nasal spray for U.S. customers. The Food and Drug Administration (FDA) granted approval for the over-the-counter distribution of Narcan spray in May. This marks the first time an OTC status has been granted to a naloxone product, allowing consumers to purchase without a prescription.
Over-the-counter Narcan sprays provide enhanced accessibility to a pivotal tool in opioid-related emergencies. Broader availability of Narcan spray helps consumers promptly respond to opioid crises, thereby potentially saving lives. Commencing in September, the naloxone HCl nasal spray (4 mg) will make its nationwide debut on retail shelves and online retail platforms for $44.99 per carton, or roughly $22.50 per dose.
Image Credit: Emergent BioSolutions
Key Themes Behind This Trend
- Enhanced Accessibility OTC
- The over-the-counter Narcan sprays provide enhanced accessibility to a pivotal tool in opioid-related emergencies.
- Broader Availability Narcan Spray
- Broader availability of Narcan spray helps consumers promptly respond to opioid crises, thereby potentially saving lives.
- Nationwide Debut Naloxone Hcl
- Commencing in September, the naloxone HCl nasal spray (4 mg) will make its nationwide debut on retail shelves and online retail platforms.
Where This Applies
- Pharmaceuticals
- The pharmaceutical industry can explore opportunities in the production and distribution of over-the-counter Narcan sprays.
- Retail
- The retail industry can benefit from the nationwide debut of naloxone HCl nasal spray, offering a potentially life-saving product to consumers.
- E-commerce
- The e-commerce industry can facilitate the online sale and distribution of Narcan nasal spray, making it more easily accessible to consumers.
